JonathanAJavitchMD
Psychiatry • New York, NYLieber Professor of Experimental Therapeutics (in Psychiatry) Professor of Pharmacology (in the Center for Molecular Recognition and in Physiology and Cellular Biophysics) Chief, Division of Molecular Therapeutics Director, Lieber Center for Schizophrenia Research and Treatment
Dr. Javitch is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
630 W 168th St
# Center
New York, NY 10032Phone+1 212-305-7308Fax+1 775-898-5133
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Psychiatry, 1986 - 1990
Johns Hopkins University School of MedicineClass of 1986
Certifications & Licensure
NY State Medical License 1987 - 2025- American Board of Psychiatry and Neurology Psychiatry
Publications & Presentations
PubMed
- 903 citationsStructure of the human dopamine d3 receptor in complex with a d2/d3 selective antagonist.Ellen Y.T. Chien, Wei Liu, Qiang Zhao, Vsevolod Katritch, Gye Won Han
Science. 2010-11-19 - 92 citationsA new mechanism of allostery in a G protein–coupled receptor dimerJ. Robert Lane, Prashant Donthamsetti, Jeremy Shonberg, Christopher J Draper-Joyce, Samuel Dentry
Nature Chemical Biology. 2014-09-01 - 53 citationsThe tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors.Elena Silvano, Millan Mark, Clotilde Mannoury la Cour, Yang Han, Lihua Duan
Molecular Pharmacology. 2010-11-01
Journal Articles
- Arrestin Recruitment to Dopamine D2 Receptor Mediates Locomotion but Not Incentive MotivationJonathan Javitch, MD, Nature
Press Mentions
2022 Leading Research AchievementsJanuary 5th, 2023- CUIMC Update - April 12, 2021April 12th, 2021
- HDRF Honors Taraji P. Henson and Jane Pauley at 14th Virtual Annual HOPE LuncheonNovember 20th, 2020
- Join now to see all
Grant Support
- P3 - Regulation Of Dopamine Transporter FunctionNational Institute On Drug Abuse2011–2012
- Functional Properties Of Protein Segments In Receptors And TransportersNational Institute On Drug Abuse2009–2012
- Training In Schizophrenia And Psychotic Disorders: From Animal Models To PatientsNational Institute Of Mental Health2010–2011
- Molecular Mechanisms Of Bacterial Homologs Of Neurotransmitter:Sodium SymportersNational Institute On Drug Abuse2009–2011
- Structure And Function Of Dopamine ReceptorsNational Institute Of Mental Health2008–2011
- Molecular Determinants For The Action Of PsychostimulantsNational Institute On Drug Abuse2007–2011
- Schizophrenia Research FellowshipNational Institute Of Mental Health2007–2009
- Structure And Function Of The Dopamine TransporterNational Institute On Drug Abuse2005–2009
- Dopamine Transporter: Substrate &Cocaine Binding SitesNational Institute On Drug Abuse2006–2007
- Archaeal &Bacterial Homologs Of Dopamine TransporterNational Institute On Drug Abuse2003–2007
- Structure Of The Dopamine D2-Like Receptor Binding SitesNational Institute Of Mental Health2006
- Molecular Recognition Of Antipsychotic Drugs And CocaineNational Institute Of Mental Health1997–2006
- 2004 &2006 Membrane Transport Proteins Gordon ConferenceNational Institute Of Mental Health2004–2005
- Dopamine Transporter: Substrate &Cocaine Binding SitesNational Institute On Drug Abuse2003–2005
- Structure Of The Dopamine D2-Like Receptor Binding SitesNational Institute Of Mental Health2002–2005
- Archaeal &Bacterial Homologs Of Dopamine TransporterNational Institute On Drug Abuse2001–2002
- Structure/Function Of The Human Dopamine TransporterNational Institute On Drug Abuse1999–2002
- Dopamine Transporter--Substrate &Cocaine Binding SitesNational Institute On Drug Abuse1998–2002
- Structure Of The Dopamine D2 &D4 Receptor Binding SitesNational Institute Of Mental Health1995–2001
- Molecular Recognition Of Antipsychotic DrugsNational Institute Of Mental Health1995–1996
- Molecular Recognition Of Antipsychotic DrugsNational Institute Of Mental Health1992–1994
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
